Evidence map›Paper›PMID 42783947›Full record

ArticleJournal of fungi (Basel, Switzerland)2026

Invasive Aspergillosis Complicating Severe COVID-19: Cumulative Incidence, Risk Factors, and Outcomes Between the First Wave of the Pandemic and Subsequent Waves, According to the ECMM/ISHAM Classification and a Local Case Assessment.

Marion Blaize, Charles Gibert, Dimitri Kornblum, Sophie Demeret, Jean-Michel Constantin, Antoine Monsel, Julien Mayaux, Charles-Edouard Luyt, Alexandre Lampros, Laure Kamus and 1 more

Abstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marion BlaizeParasitologie-Mycologie, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.ORCID 0000-0003-4432-7665
Charles GibertParasitologie-Mycologie, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.ORCID 0000-0001-5626-3553
Dimitri KornblumParasitologie-Mycologie, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.ORCID 0009-0005-5542-1966
Sophie DemeretRéanimation Neurologique, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.
Jean-Michel ConstantinGroupe de Recherche Clinique en Anesthésie Réanimation Médecine Périopératoire (GRC29), Département d'Anesthésie-Réanimation, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, 75013 Paris, France.ORCID 0000-0001-7634-5898
Antoine MonselRéanimation Polyvalente, Département d'Anesthésie-Réanimation, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.
Julien MayauxRéanimation Médicale Polyvalente, Département Respiration Réanimation Réhabilitation Sommeil (R3S), Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.
Charles-Edouard LuytMédecine Intensive Réanimation, Institut de Cardiologie, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.
Alexandre LamprosParasitologie-Mycologie, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.
Laure KamusParasitologie-Mycologie, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.
Arnaud FekkarParasitologie-Mycologie, Groupe Hospitalier La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France.ORCID 0000-0001-9954-075X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of severe COVID-19 as an independent risk factor for invasive aspergillosis remains debated, with reported incidences varying widely across studies. We compared the cumulative incidence, risk factors, and outcomes of invasive pulmonary mold infection (IPMI) in intensive care unit patients with confirmed COVID-19 during the first epidemic wave and subsequent waves up to March 2021 at La Pitié-Salpêtrière Hospital, Paris, France. Patients were systematically screened for fungal infections and classified according to ECMM/ISHAM criteria and a more stringent local assessment. The study included 259 patients (

Indexed as

AspergillusCAPAclassification criteriacolonizationcorticosteroidsmoldsSARS-CoV-2

Identifiers

PMID42783947
PMCPMC13608678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.